Ekso Bionics

copy 2021 Ekso Bionics Holdings Inc All Rights Reserved

HC Wainwright Global Life Sciences ConferenceMarch 9-10 2021

copy 2021 Ekso Bionics Inc Page 2

Forward looking statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements Forward-looking statements may include without limitation statements regarding (i) the plans objectives and expectations of management for future operations including plans objectives and expectations relating to the design development and commercialization of human exoskeletons (ii) a projection of financial results financial condition capital expenditures capital structure or other financial items (iii) the Companys future financial performance and (iv) the joint venture in China including its implementation and successful operation (v) number or percentage of patients or workers that could potentially benefit from the Companyrsquos products and (vi) the assumptions underlying or relating to any statement described in points (i) (ii) (iii) (iv) or (v) above Such forward-looking statements are not meant to predict or guarantee actual results performance events or circumstances and may not be realized because they are based upon the Companys current projections plans objectives beliefs expectations estimates and assumptions and are subject to a number of risks and uncertainties and other influences many of which the Company has no control over Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include without limitation the Companys inability to obtain adequate financing to fund the Companys operations and necessary to develop or enhance our technology the significant length of time and resources associated with the development of the Companys products the Companys failure to achieve broad market acceptance of the Companys products the failure of our sales and marketing organization or partners to market our products effectively adverse results in future clinical studies of the Companys medical device products the failure to obtain or maintain patent protection for the Companys technology failure to obtain or maintain regulatory approval to market the Companys medical devices lack of product diversification existing or increased competition regulatory intervention resulting in the inability of the Company to execute its strategic plans and the Companys failure to implement the Companys business plans or strategies These and other factors are identified and described in more detail in the Companys public filings with the Securities and Exchange Commission (SECrdquo) You should carefully read our Cautionary Note Regarding Forward-Looking Statements and the factors described in the Risk Factors section of the Companyrsquos public filings with the SEC to better understand the risks and uncertainties inherent in our business The Company does not undertake to update these forward-looking statements

Our MissionTo amplify human motion by

enhancing strength endurance and mobility across medical and industrial applications with advanced robotics

copy 2021 Ekso Bionics Inc Page 4

Therapy Advantages

Elevating the standard of care for Neurorehabilitation

EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes

ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo

ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan

CLICK TO WATCH VIDEO

copy 2021 Ekso Bionics Inc Page 2

Forward looking statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements Forward-looking statements may include without limitation statements regarding (i) the plans objectives and expectations of management for future operations including plans objectives and expectations relating to the design development and commercialization of human exoskeletons (ii) a projection of financial results financial condition capital expenditures capital structure or other financial items (iii) the Companys future financial performance and (iv) the joint venture in China including its implementation and successful operation (v) number or percentage of patients or workers that could potentially benefit from the Companyrsquos products and (vi) the assumptions underlying or relating to any statement described in points (i) (ii) (iii) (iv) or (v) above Such forward-looking statements are not meant to predict or guarantee actual results performance events or circumstances and may not be realized because they are based upon the Companys current projections plans objectives beliefs expectations estimates and assumptions and are subject to a number of risks and uncertainties and other influences many of which the Company has no control over Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include without limitation the Companys inability to obtain adequate financing to fund the Companys operations and necessary to develop or enhance our technology the significant length of time and resources associated with the development of the Companys products the Companys failure to achieve broad market acceptance of the Companys products the failure of our sales and marketing organization or partners to market our products effectively adverse results in future clinical studies of the Companys medical device products the failure to obtain or maintain patent protection for the Companys technology failure to obtain or maintain regulatory approval to market the Companys medical devices lack of product diversification existing or increased competition regulatory intervention resulting in the inability of the Company to execute its strategic plans and the Companys failure to implement the Companys business plans or strategies These and other factors are identified and described in more detail in the Companys public filings with the Securities and Exchange Commission (SECrdquo) You should carefully read our Cautionary Note Regarding Forward-Looking Statements and the factors described in the Risk Factors section of the Companyrsquos public filings with the SEC to better understand the risks and uncertainties inherent in our business The Company does not undertake to update these forward-looking statements

Our MissionTo amplify human motion by

enhancing strength endurance and mobility across medical and industrial applications with advanced robotics

copy 2021 Ekso Bionics Inc Page 4

Therapy Advantages

Elevating the standard of care for Neurorehabilitation

EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes

ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo

ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan

CLICK TO WATCH VIDEO

Our MissionTo amplify human motion by

enhancing strength endurance and mobility across medical and industrial applications with advanced robotics

copy 2021 Ekso Bionics Inc Page 4

Therapy Advantages

Elevating the standard of care for Neurorehabilitation

EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes

ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo

ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan

CLICK TO WATCH VIDEO

copy 2021 Ekso Bionics Inc Page 4

Therapy Advantages

Elevating the standard of care for Neurorehabilitation

EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes

ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo

ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan

CLICK TO WATCH VIDEO

copy 2021 Ekso Bionics Inc Page 5

Global Patient Population

18-78m Global2 288k1 USpeople currently live with Spinal

Cord Injury (SCI)

69m Global5 28m6 USpeople suffer a Traumatic Brain Injury

(TBI) each year

4 httpswwwcdcgovstrokefactshtm5 httpswwwncbinlmnihgovpubmed297015566 httpswwwcdcgovmmwrvolumes66ssss6609a1htm7 httpswwwhealthlinecomhealthmultiple-sclerosisfacts-statistics-infographic1

Spinal Cord InjuryTraumatic Brain Injury

15m Global3 800k4 USpeople suffer a Stroke each year

Stroke Multiple Sclerosis

23m Global7 10m7 US

people currently live with Multiple Sclerosis (MS)

bull Cerebral Palsybull Parkinsonsbull Orthopedic and post-surgical

recoverybull Many others

Covered under current IFU

1 httpswwwncbinlmnihgovpmcarticlesPMC41798332 httpswwwnsciscuabedupublic_pagesFactsFiguresArchivesFacts20and20Figures20-202018pdf3 httpwwwstrokecenterorgpatientsabout-strokestroke-statistics

Other Potential Indications

ABI indication includes most causes of brain injuries bull Strokebull Brain tumorsbull Surgical injuriesbull Hypoxia Anoxia

bull TBIbull Aneurysmsbull Degenerative and metabolic conditionsbull Infections and surgical injuries

copy 2021 Ekso Bionics Inc Page 6

US Market Structure and Opportunity

Inpatient Rehab (IRF)~1300 centers

~10 penetrationAvg LOS 15-20 days

Long Term Acute Care (LTACH) ~600 centers

Pilots in progressAvg LOS 20+ days

Skilled Nursing Facility (SNF) ~15000 centers

Pilots in progressAvg LOS Indefinite

OutpatientAcute Care

Future market opportunityOutpatient and home are potential future target markets

HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab

Patient Service Intensity

63000 centersEarly progress

Avg LOS 5-7 Days

Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop

Post-Acute Care(current focus)

Annual Global Market Opportunity ~$650-$900m

copy 2021 Ekso Bionics Inc Page 7

Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR

1870+Patients Studied

2200+ Target Enrollment

58Spinal Cord Injury

23Stroke

8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses

Complete

74 36Ongoing

110 Research Trials amp Clinical Outcomes Globally

THE MOST STUDIED EXOSKELETON

copy 2021 Ekso Bionics Inc Page 8

EksoNR can increase revenue by I Increase RevenuePatient

Patients can undergo longer treatment at higher reimbursement

II Attract New Patient VolumeEksoNR attracts incremental patients

III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput

Customer Case Studies

II Attract New Patients2

bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue

III Increase Patient Throughput2

bull Average length of stay (LOS) decreased from 159 days to 141 days

bull ~13 improvement in effective patient throughput

Economic DriversI Increase Revenue Patient1

1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)

EksoNR is strategic differentiator for Stroke Centers

Economic value proposition of

copy 2021 Ekso Bionics Inc Page 9

Adoption DriversDemonstrated Customer Value

bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics

Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing

+400 centers

Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale

170+250+ 30Centers with devicesDevices shipped Sites with multiple devices

US Adoption of

copy 2021 Ekso Bionics Inc Page 10

Addition of Subscription Offering

bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging

bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering

bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths

bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer

bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster

versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates

copy 2021 Ekso Bionics Inc Page 11

Ekso Bionicsrsquo Global Presence

300+ centers 450+ devices shipped 130+ million steps amp counting

Direct

Distributor

Global HeadquartersRichmond CA

EMEA HeadquartersHamburg GE

APAC HeadquartersSingapore

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 7

Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR

1870+Patients Studied

2200+ Target Enrollment

58Spinal Cord Injury

23Stroke

8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses

Complete

74 36Ongoing

110 Research Trials amp Clinical Outcomes Globally

THE MOST STUDIED EXOSKELETON

copy 2021 Ekso Bionics Inc Page 8

EksoNR can increase revenue by I Increase RevenuePatient

Patients can undergo longer treatment at higher reimbursement

II Attract New Patient VolumeEksoNR attracts incremental patients

III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput

Customer Case Studies

II Attract New Patients2

bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue

III Increase Patient Throughput2

bull Average length of stay (LOS) decreased from 159 days to 141 days

bull ~13 improvement in effective patient throughput

Economic DriversI Increase Revenue Patient1

1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)

EksoNR is strategic differentiator for Stroke Centers

Economic value proposition of

copy 2021 Ekso Bionics Inc Page 9

Adoption DriversDemonstrated Customer Value

bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics

Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing

+400 centers

Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale

170+250+ 30Centers with devicesDevices shipped Sites with multiple devices

US Adoption of

copy 2021 Ekso Bionics Inc Page 10

Addition of Subscription Offering

bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging

bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering

bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths

bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer

bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster

versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates

copy 2021 Ekso Bionics Inc Page 11

Ekso Bionicsrsquo Global Presence

300+ centers 450+ devices shipped 130+ million steps amp counting

Direct

Distributor

Global HeadquartersRichmond CA

EMEA HeadquartersHamburg GE

APAC HeadquartersSingapore

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 8

EksoNR can increase revenue by I Increase RevenuePatient

Patients can undergo longer treatment at higher reimbursement

II Attract New Patient VolumeEksoNR attracts incremental patients

III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput

Customer Case Studies

II Attract New Patients2

bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue

III Increase Patient Throughput2

bull Average length of stay (LOS) decreased from 159 days to 141 days

bull ~13 improvement in effective patient throughput

Economic DriversI Increase Revenue Patient1

1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)

EksoNR is strategic differentiator for Stroke Centers

Economic value proposition of

copy 2021 Ekso Bionics Inc Page 9

Adoption DriversDemonstrated Customer Value

bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics

Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing

+400 centers

Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale

170+250+ 30Centers with devicesDevices shipped Sites with multiple devices

US Adoption of

copy 2021 Ekso Bionics Inc Page 10

Addition of Subscription Offering

bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging

bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering

bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths

bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer

bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster

versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates

copy 2021 Ekso Bionics Inc Page 11

Ekso Bionicsrsquo Global Presence

300+ centers 450+ devices shipped 130+ million steps amp counting

Direct

Distributor

Global HeadquartersRichmond CA

EMEA HeadquartersHamburg GE

APAC HeadquartersSingapore

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 9

Adoption DriversDemonstrated Customer Value

bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics

Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing

+400 centers

Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale

170+250+ 30Centers with devicesDevices shipped Sites with multiple devices

US Adoption of

copy 2021 Ekso Bionics Inc Page 10

Addition of Subscription Offering

bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging

bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering

bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths

bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer

bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster

versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates

copy 2021 Ekso Bionics Inc Page 11

Ekso Bionicsrsquo Global Presence

300+ centers 450+ devices shipped 130+ million steps amp counting

Direct

Distributor

Global HeadquartersRichmond CA

EMEA HeadquartersHamburg GE

APAC HeadquartersSingapore

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 10

Addition of Subscription Offering

bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging

bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering

bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths

bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer

bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster

versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates

copy 2021 Ekso Bionics Inc Page 11

Ekso Bionicsrsquo Global Presence

300+ centers 450+ devices shipped 130+ million steps amp counting

Direct

Distributor

Global HeadquartersRichmond CA

EMEA HeadquartersHamburg GE

APAC HeadquartersSingapore

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 11

Ekso Bionicsrsquo Global Presence

300+ centers 450+ devices shipped 130+ million steps amp counting

Direct

Distributor

Global HeadquartersRichmond CA

EMEA HeadquartersHamburg GE

APAC HeadquartersSingapore

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 12

Industrial Exoskeleton Opportunity

Customer Problembull In US over 45m work-related injuries per

year accounting for 104m million lost production days (lsquo17)

bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions

bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries

EVO provides power without the painbull Upper-body exoskeleton designed to

increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to

the neck shoulder and backbull Reduce productivity and quality problems

associated with repetitive fatigue-related issues

EVO Value Propositions

bull Healthier workforce

bull Increased productivitybull Improved quality and craftsmanship

bull Reduced fatiguebull Increased endurance

bull Improved worker morale

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 13

Industrial exoskeleton opportunity

Market Opportunitybull Solution to a large and growing industrial

workforce problembull Initial target segments are Construction and

Food Manufacturing representing over 6m employees

bull Additional segments include warehousing logistics military utilities and mining

bull Current view of market opportunity in targeted segment is gt $5B annually

bull Existing solutions have yet to achieve product-market fit or gain significant customer traction

Manufacturing Employment 129m

Food Manufacturing 17m

Transportation Equipment 17m

Furniture 387k

Appliances 406k

Industrial Workforce Size

Construction Workers 56m

Electricians 866k

Carpenters 656k

Drywall installers 120k

Plumbers pipefitters 438k

Source US Bureau of Labor amp Statistics

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 14

Financial highlights

2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to

FY 2019 (43 CAGR for eksoHealth)

bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020

bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020

2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted

Eksorsquos responsebull Continued cost reduction efforts across the organization has

lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer

acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights

copy 2021 Ekso Bionics Inc Page 15

Financial highlights

2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement

in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20

bull FY 2020 cash utilization down $70m from 2019 or 45 YOY

bull $115m in equity financings and $129m in cash at YE 2020

bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy

Ekso management financials

• Slide Number 1
• Forward looking statements
• Slide Number 3
• Therapy Advantages
• Global Patient Population
• US Market Structure and Opportunity
• Slide Number 7
• Economic value proposition of
• US Adoption of
• Addition of Subscription Offering
• Ekso Bionicsrsquo Global Presence
• Industrial Exoskeleton Opportunity
• Industrial exoskeleton opportunity
• Financial highlights
• Financial highlights